NEW YORK (GenomeWeb News) – Power3 Medical Products today announced a definitive agreement to acquire all the stock of stem cell firm Rozetta-Cell Life Sciences.
Upon completion of the deal, expected in October or November, Rozetta-Cell will be merged with Power3 and take its name.
Terms of the deal were not disclosed.
Rozetta-Cell focuses on the delivery and imaging of stem cells during therapy. In a statement, Ira Goldknopf, president and CEO of Power3, said that the acquisition will strengthen his firm's IP portfolio "in a major growth market by merging regenerative medicine with the technologies that we are using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs."